阴道毛滴虫感染疫苗的现状与展望。
Current status and prospects for development of a vaccine against Trichomonas vaginalis infections.
机构信息
University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Division of Infectious Disease and Public Health Ontario, Ottawa, ON, Canada.
出版信息
Vaccine. 2014 Mar 20;32(14):1588-94. doi: 10.1016/j.vaccine.2013.07.050. Epub 2013 Aug 3.
Trichomonas vaginalis is a sexually transmitted pathogen with an annual worldwide incidence of over 276 million infections, the highest of all curable and non-viral STI. A large proportion of cases are asymptomatic and under-diagnosed with conventional diagnostic tools. Infection has important maternal and fetal health consequences and can lead to a higher probability of HIV transmission and susceptibility. Lack of affordable accurate diagnostic tests globally and metronidazole resistance hinder T. vaginalis control efforts. Based on data from current vaccination studies in animal models, a human vaccine is achievable to intervene on the substantial incidence of infection.
阴道毛滴虫是一种性传播病原体，全球每年有超过 2.76 亿例感染病例，是所有可治愈和非病毒性性传播感染中发病率最高的。很大一部分病例无症状且常规诊断工具漏诊。感染对母婴健康有重要影响，并可能导致 HIV 传播和易感性增加。全球缺乏负担得起的准确诊断检测以及甲硝唑耐药性阻碍了阴道毛滴虫的控制工作。基于当前动物模型疫苗研究的数据，人类疫苗是可以实现的，可以干预这种大量的感染。
Zotero 插件